Safety and Tolerability of Clobazam as Adjunctive Therapy in Paediatric Patients Aged ≥1 to ≤16 Years With Dravet Syndrome

You may be eligible if

• 1. The patient has a diagnosis of Dravet Syndrome supported by:
• 1. onset of seizures in the first year of life
• 2. history of fever-induced prolonged seizures as determined by the Investigator
• * these may include prolonged (approximately 15 minutes or longer) hemi-clonic seizures
• 3. multiple seizure types which may include:
• * generalised tonic-clonic (required for inclusion)
• * clonic (required for inclusion)
• * myoclonic jerks/seizures
• 4. history of normal development prior to seizure onset followed by development delay or regression after seizure onset
• 5. abnormal EEG consistent with Dravet Syndrome
• 2. The patient is currently receiving a stable dose of clobazam of at least 0.5 mg/kg/day (maximum 20 mg/day) for at least 3 months